Skip to content

Author

Yongming Xue

We have 2 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors

The efficacy of TIL therapy in diverse solid tumors among Asian patients is demonstrated, dynamic TCR clonal remodeling in responders is revealed, and ASS1 and CEP20 knockout as strategies to potentiate antitumor activity are identified.

Fen-Ge Li, Ji-Long Yang, Gregory A. Lizee et al. · 0 citations
#gene editing Open access Aug 2026

Genetic Engineering of Tumor‐Infiltrating Lymphocytes (TIL) via a T‐Editor Platform to Enhance Anti‐Tumor Activity

The T-Editor platform enables rapid and efficient CRISPR-mediated gene editing for engineering TIL to enhance its therapeutic potency and FAM84B may represent a novel potential target for improving TIL-mediated antitumor activity.

Fenge Li, Xuejiao Ma, Yongming Xue et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.